E. Rene Rodriguez, MD

• For additional conferences in which Dr. Rodriguez served as organizer or Chair, see Biographical Sketch.
• Chair, Cardiovascular Pathology Session, Ninth Banff Conference in Transplant Pathology, La Coruna, Spain, June 2007
• Chair, Cardiovascular Pathology Session, Eight Banff Conference in Transplant Pathology, Edmonton, Alberta, Canada, July 2005
• Task Force on the Pathology of Heart Transplantation; Humoral Rejection Workgroup,
• International Society of Heart and Lung Transplantation; Consensus Meeting on Cardiac Rejection Grading, San Francisco, Calif., April 20-22, 2004
• Chair, Cardiovascular Pathology, Proffered Papers; United States and Canadian Academy of Pathology, University of Maryland, 2006
• "Overview of Genomics in Heart Failure"; Symposium 656, Genomics of Heart Failure: Ready for Prime Time? Atlanta, Ga., February 2006

• E. Rene Rodriguez, PI Core B, Active, PO1-HL-56091, NHLBI: Mechanisms of accelerated graft arteriosclerosis (PI of Core B Direct Costs, $922,009), 2003-2088
• E. Rene Rodriguez, Inactive, P01HL70295-01, NHLBI: Delayed type hypersensitivity and IFN-? in human graft arteriosclerosis($634,987.00), 2001-2006
• PI of Core D. Tissue repository and proteomics core

See publications for this provider. (Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)

Cleveland Clinic physicians and scientists collaborate with industry to advance medical breakthroughs. These partnerships help commercialize discoveries for public benefit while maintaining scientific integrity. To ensure transparency and minimize potential bias, Cleveland Clinic reviews these relationships and publicly discloses when physicians/scientists receive significant compensation for consulting, serve in fiduciary roles, receive royalties, or hold equity interests related to their work. We manage potential conflicts through approval processes, annual reporting, and targeted management plans.

As of 2025-12-08, Dr. Rodriguez has reported no financial relationship with industry that is applicable to this listing.

In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by Cleveland Clinic. To learn more about Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.

Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers' discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.

* Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.